Cryoport, Inc. (NASDAQ:CYRX) Receives Average Rating of “Moderate Buy” from Brokerages

Cryoport, Inc. (NASDAQ:CYRX) has been given an average rating of “Moderate Buy” by the seven ratings firms that are presently covering the firm, MarketBeat Ratings reports. Three analysts have rated the stock with a hold recommendation and four have assigned a buy recommendation to the company. The average 12 month price target among brokerages that have issued ratings on the stock in the last year is $12.29.

A number of analysts have recently weighed in on CYRX shares. Guggenheim started coverage on shares of Cryoport in a research report on Thursday, December 19th. They issued a “buy” rating and a $11.00 target price on the stock. Needham & Company LLC reaffirmed a “buy” rating and issued a $11.00 target price on shares of Cryoport in a research report on Friday, January 17th. Finally, Roth Mkm reduced their target price on shares of Cryoport from $18.00 to $15.00 and set a “buy” rating on the stock in a research report on Friday, November 8th.

Cryoport Stock Up 0.4 %

Shares of Cryoport stock opened at $6.73 on Friday. The company has a current ratio of 5.70, a quick ratio of 5.32 and a debt-to-equity ratio of 0.48. The company’s fifty day simple moving average is $7.79 and its two-hundred day simple moving average is $7.82. The company has a market cap of $332.66 million, a P/E ratio of -1.99 and a beta of 1.59. Cryoport has a 12-month low of $5.32 and a 12-month high of $20.10.

Insider Activity at Cryoport

In related news, Director Ramkumar Mandalam sold 7,369 shares of the stock in a transaction dated Monday, December 2nd. The shares were sold at an average price of $7.46, for a total transaction of $54,972.74. Following the sale, the director now directly owns 59,497 shares of the company’s stock, valued at approximately $443,847.62. This represents a 11.02 % decrease in their position. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, CEO Jerrell Shelton sold 50,000 shares of the stock in a transaction dated Thursday, November 21st. The shares were sold at an average price of $6.51, for a total transaction of $325,500.00. Following the sale, the chief executive officer now directly owns 731,897 shares in the company, valued at $4,764,649.47. This trade represents a 6.39 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last ninety days, insiders have sold 109,869 shares of company stock valued at $735,673. 10.10% of the stock is owned by insiders.

Hedge Funds Weigh In On Cryoport

Hedge funds and other institutional investors have recently bought and sold shares of the stock. Avanza Fonder AB bought a new position in Cryoport during the 4th quarter valued at about $64,000. Quarry LP bought a new position in Cryoport during the 4th quarter valued at about $69,000. Dynamic Technology Lab Private Ltd bought a new position in Cryoport during the 3rd quarter valued at about $82,000. Nebula Research & Development LLC lifted its stake in Cryoport by 21.6% during the 4th quarter. Nebula Research & Development LLC now owns 12,442 shares of the company’s stock valued at $97,000 after acquiring an additional 2,207 shares during the period. Finally, Russell Investments Group Ltd. lifted its stake in Cryoport by 135.5% during the 4th quarter. Russell Investments Group Ltd. now owns 12,875 shares of the company’s stock valued at $100,000 after acquiring an additional 7,407 shares during the period. Institutional investors own 92.90% of the company’s stock.

About Cryoport

Cryoport, Inc provides temperature-controlled supply chain solutions in biopharma/pharma, animal health, and human reproductive medicine markets in the Americas, Europe, the Middle East, Africa, and the Asia Pacific. The company offers Cryoport Express Shippers; Cryoport ELITE -80°C Gene Therapy Shipper; Cryoport ELITE Cryosphere Shipper; Cryoport consulting services, including physical, thermal, and shipping qualifications of shipping systems and/or packaging to developing custom packaging solutions; and Cryoport bioservices, such as controlled temperature storage, fulfilment, kit production, secondary packaging, labelling of therapeutic products, and GMP raw materials storage services.